Merit Medical Systems

What Merit Medical Systems does

Merit Medical Systems, Inc. (NASDAQ: MMSI) is a publicly traded medical device manufacturer founded in 1987 and headquartered in South Jordan, Utah. The company designs, manufactures, and markets proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, with a product portfolio spanning more than 20 categories including access devices, balloons, biopsy tools, catheters, dialysis access products, embolic delivery systems, guidewires, inflation devices, stents, and structural heart products. Flagship franchises include the WRAPSODY Cell-Impermeable Endoprosthesis (the company's first FDA premarket approval product, approved December 2024 for dialysis vascular access), the ViaVerte basivertebral nerve ablation system for chronic lower back pain (exclusively distributed by Medtronic), the SCOUT radar localization system for breast surgery, the Embosphere microsphere embolization platform, the SOLO PACE FUSION temporary pacing system for TAVR, the C2 CryoBalloon ablation system, and the OneMark detection imaging system acquired from View Point Medical.

The company serves five primary clinical segments — interventional cardiology, interventional radiology, oncology, critical care, and gastroenterology/endoscopy — selling to hospitals and physicians worldwide. Distribution combines a direct field sales force of more than 700 sales and clinical support personnel in the United States (with international counterparts bringing total commercial staff to more than 500), exclusive OEM partnerships such as the Medtronic deal for ViaVerte, and a distributor network spanning 40+ countries. Revenue is generated through hardware sales of single-use disposable devices; pricing is negotiated bilaterally with healthcare institutions and group purchasing organizations and is not publicly disclosed.

Merit reported FY2025 net sales of $1.516 billion, up approximately 11.8% YoY, with FY2025 net income of $128.5 million, free cash flow of $216 million, and Q4 2025 non-GAAP operating margins of 21%. The company employs approximately 7,100 people globally, with manufacturing operations in Utah and Galway, Ireland, and a market capitalization of approximately $4.02 billion as of April 2026. The business is undergoing a major leadership transition: founder Fred Lampropoulos stepped down after 38 years, Martha G. Aronson was appointed CEO in October 2025, and the company is executing an active acquisition program (Cook Medical lead management $210M, Endogastric Solutions $105M, Biolife $120M, C2 CryoBalloon $22M, View Point Medical $140M) while raising FY2026 guidance to approximately $1.612–$1.634 billion.

Name

Merit Medical Systems

Legal name

Merit Medical Systems, Inc.

Website

https://merit.com

Company type

Public

Founded year

1987

Operating status

Operating

Headcount range

5,001–10,000 employees

Short description

Merit Medical Systems manufactures proprietary disposable medical devices for interventional cardiology, radiology, oncology, critical care, and endoscopy procedures, serving hospitals and physicians globally through a 700+ direct sales force and distributor network across 40+ countries.

Ownership category

akta.pro rank

Product category

Interventional Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Medical Equipment and Supplies Manufacturing (3391), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Single-Use Medical Disposables & Procedure Kits (Drapes, Tubing, Catheters, Syringes, Custom Packs) (HLAHANAG)

akta.pro secondary industries

Single-Use Surgical Devices & Procedure Packs (Disposable instruments, drapes, kits) (HLAHADAM), Sharps Safety, Needlestick Prevention & Disposal (Safety Devices, Sharps Containers) (HLAHANAH), Contrast Media Injectors & Radiology Accessories (HLAHABAK)

Keywords

• Interventional medical devices
• Disposable medical devices
• Cardiology devices
• Radiology devices
• Endoscopy devices

Headquarters

HQ city

South Jordan

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Supply Chain, Operations, Technology or R&D, Marketing or Sales

Revenue model

1. Disposable Medical Devices Sales: Merit Medical generates revenue through the manufacture and sale of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures. Products are sold directly to hospitals and physicians through a global sales force and through distribution partners.
2. Product Acquisitions and Integration: Merit grows revenue through strategic acquisitions of complementary medical device technologies (View Point Medical, Cook Medical lead management portfolio, C2 CryoBalloon, Biolife) which are integrated into existing sales channels.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels5 records

Core offering

Merit Medical Systems manufactures and sells proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures across cardiology, radiology, oncology, critical care, and endoscopy specialties. The company develops, produces, and markets a comprehensive portfolio including covered stents, embolic microspheres, biopsy devices, sheath introducers, cryoablation systems, pacing systems, and tumor localization technologies sold directly to hospitals and physicians worldwide.

Product overview

Merit Medical Systems is a manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures. The company operates as a platform of diverse product categories including Access, Accessories, Balloons, Biopsy, Catheters, Compression, Dialysis Access, Drainage, Electrophysiology, Embolics & Delivery Systems, GERD Treatment, Guide Wires, Inflation Devices, Interventional Spine, Oncology, Stents, and Structural Heart. Key products include the WRAPSODY CIE (the company's first PMA-approved covered stent for dialysis access), Embosphere Microspheres for embolotherapy, SOLO PACE FUSION pacing system for TAVR, C2 CryoBalloon ablation system, ViaVerte basivertebral nerve ablation system, OneMark tumor localization products (from View Point Medical acquisition), Resilience TTS Esophageal Stent, StatSeal hemostatic sealant (from Biolife acquisition), SCOUT radar localization, and comprehensive biopsy and access device portfolios. The company serves cardiology, radiology, oncology, critical care, and endoscopy specialties through a global distribution network.

Differentiator

Problem solved

Functional benefit

Brands

• WRAPSODY: Cell-Impermeable Endoprosthesis (CIE) - FDA-approved covered stent for dialysis access procedures
• Prelude
• SCOUT
• Elation
• ViaVerte
• StatSeal

Products and services

• WRAPSODY CIE (Cell-Impermeable Endoprosthesis) Merit's first premarket approval (PMA) covered stent designed to restore vascular access for hemodialysis patients with venous obstructions. Features a cell-impermeable membrane to prevent tissue ingrowth.
• Embosphere Microsphere Embolic microsphere product used in embolotherapy procedures for treatment of conditions including uterine fibroids, liver tumors, and genicular artery embolization (GAE) for knee osteoarthritis. CE-marked under EU MDR for GAE.
• SOLO PACE FUSION Temporary Pacing System Left ventricular pacing system purpose-built for modern TAVR procedures, designed to offer efficiency and reduced pacing risk with a standardized, simplified workflow.
• C2 CryoBalloon Ablation System Cryoablation technology for endoscopic treatment of Barrett's Esophagus with dysplasia and Gastric Antral Vascular Ectasia (GAVE). Acquired from PENTAX Medical in 2025.
• ViaVerte Basivertebral Nerve Ablation System FDA-cleared system for treating chronic vertebrogenic lower-back pain through basivertebral nerve ablation. Features a physician-controlled steerable mechanism for precise nerve targeting. Distributed exclusively through Medtronic.
• OneMark Detection Imaging System and OneMark Tissue Markers FDA-cleared ultrasound-based tumor localization system and tissue markers used in breast and soft tissue tumor localization procedures. Acquired through View Point Medical merger in April 2026.
• Resilience Through-the-Scope Esophageal Stent Through-the-scope esophageal stent designed to treat esophageal fistulas and strictures caused by malignant tumors. Features proprietary anti-migration flanges and single-handed deployment system with sizes (14mm x 50mm, 17mm x 50mm, 20mm x 50mm) offering high migration resistance.
• StatSeal Topical Hemostatic Sealant Topical hemostatic sealant for rapid control of moderate-to-severe bleeding at vascular procedure sites. Part of Merit portfolio following Biolife acquisition.
• SCOUT Radar Localization System Radar-based breast tumor localization technology for wire-free, non-radioactive marking of lesions during biopsy and surgical procedures.
• BioSentry Tract Sealant System First biopsy sealant system designed specifically to address biopsy-related pneumothorax. Features a self-expanding plug providing an airtight seal.
• TEMNO Elite Biopsy System Soft tissue biopsy device with features designed to provide superior tissue samples and total procedure control. Part of Merit's comprehensive biopsy portfolio.
• TEMNO Evolution Biopsy Device Compact, ergonomically contoured biopsy device with tactile-enhanced plunger for one-handed operation during breast, kidney, liver, lung, and thyroid biopsies.
• Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology Radial access sheath with thin-wall design and best-in-class insertion and sheath retention features for confident vascular access procedures.
• Prelude IDeal Hydrophilic Sheath Introducer Hydrophilic sheath designed for radial artery access from the wrist or hand.
• ClariVein OC Infusion Catheter Infusion catheter with unique 360-degree rotatable dispersion wire at distal end for controlled dispersion of physician-specified agents to the peripheral vasculature.
• ClariVein IC Infusion Catheter Specialty infusion catheter with rotating wire tip for controlled 360-degree dispersion of agents to peripheral vasculature.
• Elation5 Fixed-Wire Dilation Balloon First and only 5-stage esophageal dilation balloon in the market, expanding treatment range with a single balloon while maintaining premium quality design.
• ASAP and ASAPLP Aspiration Catheters Aspiration catheters for thrombus removal in peripheral vasculature procedures, with all-inclusive accessory kit and tray for convenience.
• Preston Bone Biopsy Accessories Bone biopsy accessories including introducers, needles, drills, and bone fillers for bone biopsy procedures.

Quantifiable outcome

• 21.7% revenue growth in cardiac intervention products in 2025
• +2 more outcomes

Named customers1 record

Segments6 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered core and minor.

• View Point MedicalcoreStrategic or Co-development Partner · 1 April 2026Merit Medical acquired View Point Medical, Inc. through a merger for approximately $140 million. View Point becomes a wholly-owned subsidiary of Merit. The acquisition brings the OneMark Detection Imaging System and OneMark Tissue Markers, FDA-cleared products used in breast and soft tissue tumor localization procedures. This acquisition expands Merit's therapeutic oncology portfolio.
• MedtroniccoreChannel Partner/ Reseller/ Distributor · 24 March 2026Medtronic entered into an exclusive distribution agreement with Merit Medical to offer the FDA-cleared ViaVerte basivertebral nerve ablation system for treating chronic vertebrogenic lower back pain. The ViaVerte system is the first and only BVNA system with a physician-controlled steerable mechanism. This agreement expands Medtronic's pain management portfolio while leveraging Merit's product development capabilities.
• PENTAX MedicalminorStrategic or Co-development Partner · 15 October 2025Merit Medical signed an asset purchase agreement with PENTAX Medical to acquire the C2 CryoBalloon device and related technology for $22 million. The acquisition expands Merit's endoscopy portfolio and is projected to generate $6 million to $8 million in revenue in 2026.
• Cook MedicalcoreStrategic or Co-development Partner · 1 November 2024Merit Medical completed the acquisition of Cook Medical's lead management portfolio for approximately $210 million, funded through cash and borrowings. The acquisition strengthens Merit's position in cardiac intervention markets and expands its electrophysiology offerings.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Cook Medical: Private medical device manufacturer with a broad interventional portfolio. Recently sold its lead management portfolio to Merit and competes across interventional radiology and cardiology.
• AngioDynamics: Mid-cap medical device company focused on interventional oncology, vascular access, and peripheral vascular disease. Closely comparable to Merit's oncology, biopsy, and access segments.
• Penumbra Inc. Specialty medical device company with peripheral vascular thrombectomy, embolization, and neurosurgical stroke products. Comparable to Merit in embolics and aspiration catheter categories.
• Teleflex Incorporated: Medical device company with strong interventional access, cardiology, and surgical product portfolios. Highly comparable to Merit in scale, customer base, and disposable product focus.

Broad incumbents

• Medtronic: World's largest medical device company, with deep interventional cardiology, structural heart, and pain management portfolios. Merit's distribution partner for ViaVerte and a direct competitor in many disposable categories.
• Boston Scientific: Global medical device leader with a broad interventional cardiology, peripheral intervention, and oncology portfolio. Overlaps with Merit across multiple catheter-based categories and competes for hospital contracts.
• Abbott Laboratories: Diversified medical device leader with strong interventional cardiology, vascular, and structural heart businesses. Direct competitor to Merit in catheters, stents, and guide wires.
• Becton Dickinson (BD): Global medical device company with significant vascular access, biopsy, and disposable device portfolios. Competes with Merit in biopsy needles, access devices, and hospital disposables.

Emerging players

• Inari Medical: Medical device company specializing in venous thromboembolism treatment. Comparable in interventional focus and overlaps with Merit's peripheral vascular and aspiration portfolio.

Others

• Cardiovascular Systems (acquired by Abbott): Former independent peripheral vascular intervention company, led by Scott Ward (now on Merit's board) before its acquisition by Abbott. Comparable in scale and peripheral atherectomy focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/meritmedical
• YouTubeyoutube.com/user/meritmedical
• Facebookfacebook.com/meritmedicalsystems
• LinkedInlinkedin.com/company/merit-medical-systems-inc
• Instagraminstagram.com/meritmedical

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries5 records

Funding overview

Funding rounds3 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A12 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Merit Medical Systems